1 Derivation and Internal Validation of Prediction Models for

2 Pulmonary Hypertension Risk Assessment in a Cohort


3 Inhabiting Tibet, China


- 4 Authors
- 5 Junhui Tang¹, Rui Yang², Hui Li¹, Xiaodong Wei¹, Zhen Yang¹, Wenbin Cai¹, Yao Jiang¹,
- 6 Ga Zhuo¹, Li Meng¹, Yali Xu³*
- 7 Junhui Tang and Rui Yang contributed equally to this work.
- 9 Affiliations


8


15


- 10 1. Department of Ultrasound, the General Hospital of Tibet Military Area Command, Tibet,
- 11 China
- 12 2. Department of High Mountain Sickness, the General Hospital of Tibet Military Area
- 13 Command, Tibet, China
- 14 3. Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China
- 16 Corresponding author *
- 17 Yali Xu, MD, PhD
- Department of Ultrasound, Xinqiao Hospital, Army Medical University, 83 Xinqiao Main Street,
- 19 Shapingba District, Chongqing, 400037, PR China.
- 20 Tel.: +86 18523384936
- E-mail address: xuyali1976@163.com
- 23 This research was supported by the Talent Program of Army Medical University (No. 2019R038).

















- 1 Derivation and Internal Validation of Prediction Models for
- 2 Pulmonary Hypertension Risk Assessment in a Cohort
- 3 Inhabiting Tibet, China
- 4 Authors
- 5 Junhui Tang¹, Rui Yang², Hui Li¹, Xiaodong Wei¹, Zhen Yang¹, Wenbin Cai¹, Yao Jiang¹,
- 6 Ga Zhuo¹, Li Meng¹, Yali Xu³*
- 7 Junhui Tang and Rui Yang contributed equally to this work.

9 Affiliations

8

- 10 1. Department of Ultrasound, the General Hospital of Tibet Military Area Command, Tibet,
- 11 China
- 12 2. Department of High Mountain Sickness, the General Hospital of Tibet Military Area
- 13 Command, Tibet, China
- 14 3. Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China
- 16 Corresponding author *
- 17 Yali Xu, MD, PhD
- 18 Department of Ultrasound, Xinqiao Hospital, Army Medical University, 83 Xinqiao Main Street,
- 19 Shapingba District, Chongqing, 400037, PR China.
- 20 E-mail address: xuyali1976@163.com

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Abstract

Background: Due to exposure to hypoxic environments, individuals residing in plateau regions are susceptible to pulmonary hypertension (PH). Consequently, there is an urgent need for a simple and efficient nomogram to assess the risk of PH in this population. Methods: This study included a total of 6,603 subjects, who were randomly divided into a validation set and a derivation set at a ratio of 7:3. Optimal predictive features were identified through the least absolute shrinkage and selection operator regression technique, and nomograms were constructed using multivariate logistic regression. The performance of these nomograms was evaluated and validated using the area under the curve (AUC), calibration curves, the Hosmer-Lemeshow test, and decision curve analysis. Comparisons between nomograms were conducted using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices. **Results:** Nomogram¹ was established based on independent risk factors, including gender, Tibetan ethnicity, age, incomplete right bundle branch block (IRBBB), atrial fibrillation (AF), sinus tachycardia (ST), and T wave changes (TC). The AUCs for Nomogram^I were 0.716 in the derivation set and 0.718 in the validation set. Nomogram^{II} was established based on independent risk factors, including Tibetan ethnicity, age, right axis deviation (RAD), high voltage in the right ventricle (HVRV), IRBBB, AF, pulmonary P waves, ST, and TC. The AUCs for Nomogram^{II} were 0.844 in the derivation set and 0.801 in the validation set. Both nomograms demonstrated satisfactory clinical consistency. The IDI and NRI indices confirmed that Nomogram^{II} outperformed Nomogram^I. Therefore, the online dynamic Nomogram^{II} was established.

Conclusions: A reliable and straightforward nomogram was developed to predict the risks of PH in the plateau population.

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

44

43

Introduction

Pulmonary hypertension (PH) is a chronic, progressive condition characterised by elevated pulmonary arterial pressure, primarily resulting from pulmonary vascular remodelling. This remodelling is driven by the infiltration of inflammatory cells, endothelial-to-mesenchymal transition, and hyperplasia of the pulmonary intima (Rubin & Naeije, 2023; Shah, Beckmann, Vorla, & Kalra, 2023; Simonneau et al., 2019). PH often presents similarly to other lung diseases, leading to diagnostic delays and, consequently, delays in receiving optimal treatment. Approximately 1% of the adult population and more than half of individuals with congestive heart failure are affected by PH (Hoeper et al., 2016; Mandras, Mehta, & Vaidya, 2020). Moreover, as the pulmonary vascular load increases, PH can ultimately lead to life-threatening right heart failure. The 1-year and 3-year survival rates for patients with PH range from 68% to 93% and 39% to 77%, respectively (Naeije, Richter, & Rubin, 2022; Ruopp & Cockrill, 2022). Right-heart catheterisation (RHC) is recognised as the gold standard for diagnosing PH, clarifying the specific diagnosis, and determining the severity of the condition. However, due to its invasive nature, RHC is not suitable as a widespread population screening tool for PH (McGoon et al., 2004). Transthoracic echocardiography (TTE), a non-invasive screening test, is extensively used for PH because it can provide estimates of pulmonary arterial systolic pressure (sPAP) and evaluates cardiac structure and function. A clinical study involving 731 patients in China found no significant difference between RHC and TTE in assessing sPAP in PH caused by hypoxia.

Furthermore, Pearson correlation analysis between RHC and TTE demonstrated a moderate overall correlation (Hong et al., 2023; McGoon et al., 2004; Xu & Jing, 2009).

According to literature reviews, nearly 140 million individuals reside in high-altitude regions (altitudes exceeding 2,500 meters), and the number of people visiting these areas for economic or recreational reasons has been increasing over the past few decades (Moore, Niermeyer, & Zamudio, 1998; West, 2012; Xu & Jing, 2009). High altitude typically signifies a hypoxic environment due to the decrease in barometric pressure as altitude increases, which proportionally reduces PO2, resulting in hypotaric hypoxia (Gassmann et al., 2021). PH arising from prolonged exposure to hypoxic conditions at high altitudes is termed high-altitude pulmonary hypertension (Xu & Jing, 2009). Hypoxia triggers hypoxic pulmonary vasoconstriction (HPV), a physiological response aimed at optimising ventilation/perfusion matching by redirecting blood to better-oxygenated segments of the lung through the constriction of small pulmonary arteries (Dunham-Snary et al., 2017). Furthermore, sustained hypoxia leads to pulmonary vascular remodelling, increasing resistance to blood flow due to reduced vessel elasticity and decreased vessel diameter. HPV and vascular remodelling are the primary mechanisms underlying hypoxia-induced PH, which significantly impairs right ventricular function and can ultimately result in fatal heart failure (Julian & Moore, 2019; Penaloza & Arias-Stella, 2007). Consequently, there is a pressing need for a straightforward and dependable model to assist clinicians and individuals in assessing the risk of PH in populations at high altitudes.

In this study, we developed and validated two risk prediction models for high-altitude PH based on TTE results by examining routine inspection parameters in Tibet, China.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Materials and methods

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Study population and data collection

Upon gathering data from all patients who underwent both TTE and 12-lead electrocardiogram (ECG) examinations at the General Hospital of Tibet Military Aera Command between April 2021 and October 2023, we further screened the records based on the following criteria: (1) age > 14 years; (2) interval between the TTE and ECG examinations < 2 months, and (3) for patients with multiple TTE and/or ECG records, only the examination with the shortest interval between TTE and ECG was selected. Ultimately, we compiled examination data for 6,603 eligible patients. The retrospectively-collected clinical data were categorised into two main groups: (1) demographic characteristics, including name, age, gender, and Tibetan ethnicity; (2) ECG results, encompassing right axis deviation (RAD), clockwise rotation (CR), counterclockwise rotation (CCR), high voltage in the right ventricle (HVRV), incomplete right bundle branch block (IRBBB), complete right bundle branch block (CRBBB), atrial fibrillation (AF), sinus arrhythmia (SA), sinus bradycardia (SB), sinus tachycardia (ST), T wave changes (TC), ST-segment changes (STC), atrial premature beats (APB), ventricular premature beats (VPB), junctional premature beats (JPB), complete left bundle branch block (CLBBB), first-degree atrioventricular block (IAB), and pulmonary P waves (PP); (3) TTE results: pulmonary arterial systolic pressure (sPAP) was measured via TTE to evaluate PH. PH was graded as follows: Grade I PH (50 mmHg > sPAP ≥ 30 mmHg), Grade II PH (70 mmHg > sPAP ≥ 50 mmHg), and Grade III PH (sPAP ≥ 70 mmHg). The severity of PH increases with its grade, indicating a higher risk of the condition. All procedures were conducted following the approval of the Ethics Committee of the General

Hospital of Tibet Military Area Command (APPROVAL NUMBER: 2024-KD002-01).

Subsequently, the data from all participants were anonymised and de-identified prior to analysis.

Consequently, the requirement for informed consent was waived.

Statistical analysis

Statistical analysis was performed with R software version 4.3.2. P < 0.05 (double-tailed) was considered statistically significant.

For validation and derivation of the prediction model, subjects were divided into a validation set and a derivation set randomly, at a ratio of 7:3, respectively. Categorical variables were transformed into dichotomous variables, and continuous variables were expressed by concrete values (means \pm standard deviation) and analysed using Student's t-test. Fisher's exact test or Pearson's $\gamma 2$ test was applied for categorical variables.

The derivation set was used to select optimal predictive factors through the least absolute shrinkage and selection operator (LASSO) regression technique. Independent factors were identified via multivariate logistic regression analysis, incorporating variables selected during the LASSO regression. A backward step-down selection process, guided by the Akaike information criterion, determined the final model. The predictive accuracy of the nomograms was assessed using the AUC of the ROC curve in both the derivation and validation sets. The Hosmer-Lemeshow test and calibration curves were employed to evaluate the consistency between actual outcomes and predicted probabilities. The clinical utility of the nomograms was assessed through decision curve analysis (DCA). The cut-off value for the total score in the nomogram was established based on the ROC curve, with patients categorised into low-risk and high-risk groups. The performance comparison between nomograms was analysed using the integrated




Figure 1. Flow diagram. Based on the exclusion and inclusion criteria, 6,603 patients were included in this study. Patients were divided into a validation set and a derivation set randomly following a 7:3 ratio. pulmonary hypertension, PH; right axis deviation, RAD; high voltage in the right ventricle, HVRV; incomplete right bundle branch block, IRBBB; atrial fibrillation, AF; sinus tachycardia, ST; T wave changes, TC; Pulmonary P waves, PP.

Results

 ${\bf Table~1.~Baseline~characteristics~of~individuals~in~the~derivation~and~validation~sets}$

Variable	Derivation set (n = 4622)	Validation set (n = 1981)	P
Age			_
Total (Mean ± SD)	42.43 ± 16.93	42.05 ± 16.41	0.390
Age≤42, n (%)	2619(56.66)	1135(57.29)	
Age>42, n (%)	2003(43.34)	846(42.71)	0.635
Tibetan, n (%)			0.538
No	2856 (61.79)	1240 (62.59)	
Yes	1766 (38.21)	741 (37.41)	
Gender, n (%)			0.260
female	1219 (26.37)	549 (27.71)	

male	3403 (73.63)	1432 (72.29)	
RAD, n (%)			0.141
No	3833 (82.93)	1672 (84.40)	
Yes	789 (17.07)	309 (15.60)	
CR, n (%)			0.387
No	4000 (86.54)	1730 (87.33)	
Yes	622 (13.46)	251 (12.67)	
CCR, n (%)			0.402
No	3994 (86.41)	1727 (87.18)	
Yes	628 (13.59)	254 (12.82)	
HVRV, n (%)			0.102
No	4151 (89.81)	1805 (91.12)	
Yes	471 (10.19)	176 (8.88)	
IRBBB, n (%)			0.573
No	4547 (98.38)	1945 (98.18)	
Yes	75 (1.62)	36 (1.82)	
CRBBB, n (%)			0.945
No	4444 (96.15)	1904 (96.11)	
Yes	178 (3.85)	77 (3.89)	
AF, n (%)			0.594

	No	4551 (98.46)	1954 (98.64)	
	Yes	71 (1.54)	27 (1.36)	
S	A, n (%)			0.243
	No	4247 (91.89)	1837 (92.73)	
	Yes	375 (8.11)	144 (7.27)	
S'	T, n (%)			0.910
	No	4395 (95.09)	1885 (95.15)	
	Yes	227 (4.91)	96 (4.85)	
S	B, n (%)			0.345
	No	4245 (91.84)	1833 (92.53)	
	Yes	377 (8.16)	148 (7.47)	
Т	C, n (%)			0.769
	No	4003 (86.61)	1721 (86.88)	
	Yes	619 (13.39)	260 (13.12)	
S'	TC, n (%)			0.415
	No	4399 (95.18)	1876 (94.70)	
	Yes	223 (4.82)	105 (5.30)	
A	PB, n (%)			0.219
	No	4587 (99.24)	1960 (98.94)	
	Yes	35 (0.76)	21 (1.06)	

JPB, n (%)			0.425
No	4603 (99.59)	1970 (99.44)	
Yes	19 (0.41)	11 (0.56)	
VPB, n (%)			0.844
No	4580 (99.09)	1962 (99.04)	
Yes	42 (0.91)	19 (0.96)	
PP, n (%)			0.439
No	4507 (97.51)	1938 (97.83)	
Yes	115 (2.49)	43 (2.17)	
CLBBB, n (%)			0.757
No	4610 (99.74)	1975 (99.70)	
Yes	12 (0.26)	6 (0.30)	
IAB, n (%)			0.910
No	4556 (98.57)	1952 (98.54)	
Yes	66 (1.43)	29 (1.46)	
PH ≥ I grade, n (%)			0.820
No	2793 (60.43)	1203 (60.73)	
Yes	1829 (39.57)	778 (39.27)	
PH ≥ II grade, n(%)			0.962
No	4227 (91.45)	1811 (91.42)	

Subjects' characteristics

Following a 7:3 allocation ratio, 4,622 subjects were placed in the derivation set and 1,981 subjects in the validation set. The characteristics of the subjects are presented in Table 1. The prevalence of PH of Grade I or higher was 39.57% (1,829 cases) in the derivation set and 39.27% (778 cases) in the validation set (P=0.820 > 0.05). The prevalence of PH of Grade II or higher was 8.55% (395 cases) in the derivation set and 8.58% (170 cases) in the validation set (P=0.962 > 0.05). No significant difference was observed in the age distribution between the derivation and validation sets (42.43 \pm 16.93 vs. 42.05 \pm 16.41, P=0.390 > 0.05), with age categorised into \leq 42 and \geq 42 subgroups based on the mean age. The composition ratios of the two age subgroups did not significantly differ between the validation and derivation sets (P=0.6352 \geq 0.05). Furthermore, no significant differences were observed in the characteristics related to gender, Tibetan or not, RAD, CR, CCR, HVRV, IRBBB, CRBBB, AF, SA, ST, SB, TC, STC, APB, VPB, JPB, PP, IAB, and CLBBB. (Table 1)

Independent risk factors in PH≥I grade group and PH≥II grade group

In the PH \geq I grade group, based on the λ _min criterion in the LASSO regression model, 18 out of 22 variables were selected. However, this selection was deemed excessive for practical clinical applications. Therefore, we further refined the model using the λ _1se criterion, which reduced the number of variables, albeit with a significant decrease in the AUC of the ROC curve (λ _1se) compared to the ROC curve (λ _min) (Fig. 2 C, E, G). Ultimately, 9 variables were chosen

according to λ _1se, including gender, Tibetan ethnicity, age \leq 42, age >42, IRBBB, CRBBB, AF, ST, and TC (Fig. 2 I). Gender, Tibetan ethnicity, age, IRBBB, AF, ST, and TC were subsequently identified as independent risk factors for PH \geq I grade through multivariate logistic regression analysis and were used to develop Nomogram^I. (Table 2)

In the PH \geq II grade group, based on the λ_{-} 1se criterion in the LASSO regression model (Fig. 2 D, F), 11 variables were selected to align with clinical needs. These variables were Tibetan ethnicity, age \leq 42, age >42, RAD, HVRV, IRBBB, CRBBB, AF, PP, ST, and TC (Fig. 2 J). Tibetan ethnicity, age, RAD, HVRV, IRBBB, AF, PP, ST, and TC were determined to be independent risk factors for PH \geq II grade through multivariate logistic regression analysis and were utilised to construct Nomogram^{II}. (Table 3).

Table 2. Risk factors for PH≥I grade in the derivation set

Variable	β -Coefficient	OR (95%CI)	P
Tibetan	0.34	1.40 (1.23-1.60)	<0.001
Gender	-0.3	0.74 (0.65-0.84)	<0.001
Age	0.034	1.03 (1.03-1.04)	<0.001
IRBBB	1.106	3.02 (1.96-4.67)	<0.001
AF	1.431	4.18 (2.19-7.97)	<0.001
ST	0.369	1.45 (1.14-1.84)	0.003
TC	0.306	1.36 (1.16-1.59)	<0.001

Table 3. Risk factors for PH≥II grade in the derivation set

Variable	β -Coefficient	OR (95%CI)	P
Tibetan	0.689	1.99 (1.55-2.57)	<0.001
Age	0.042	1.04 (1.03-1.05)	<0.001
RAD	0.751	2.12 (1.56-2.88)	<0.001
HVRV	0.486	1.63 (1.14-2.31)	0.007
IRBBB	1.512	4.53 (2.77-7.42)	<0.001
AF	2.102	8.18 (5.13-13.05)	<0.001
ST	1.247	3.48 (2.58-4.70)	<0.001
TC	0.592	1.81 (1.44-2.27)	<0.001
PP	1.486	4.42 (2.96-6.61)	<0.001




Figure 2 illustrates the optimal predictive variables as determined by the LASSO binary logistic regression model. Panels A and B depict the measurement of tricuspid regurgitation

spectra via transthoracic echocardiography in patients with Grade I PH (A) and Grade III PH (B). Panels C to J demonstrate the identification of the optimal penalisation coefficient lambda (λ) in the LASSO model using 10-fold cross-validation for the PH \geq I grade group (C) and the PH \geq II grade group (D). The dotted line on the left (λ _min) represents the value of the harmonic parameter $\log(\lambda)$ at which the model's error is minimised, and the dotted line on the right (λ _1se) indicates the value of the harmonic parameter $\log(\lambda)$ at which the model's error is minimal minus 1 standard deviation. The LASSO coefficient profiles of 22 predictive factors for the PH \geq I grade group (E) and the PH \geq II grade group (F) show that as the value of λ decreased, the degree of model compression increased, enhancing the model's ability to select significant variables. ROC curves were constructed for three models (LASSO, LASSO- λ _min, LASSO- λ _1se) in both the PH \geq I grade group (G) and the PH \geq II grade group (H). Histograms depict the final variables selected according to λ _1se and their coefficients for the PH \geq I grade group (I) and the PH \geq II grade group (J). Asterisks denote levels of statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001.

Construction of Nomogram^I in PH≥I grade group and Nomogram^{II} in PH≥II grade group

In the PH≥I grade group, a predictive Nomogram^I for PH≥I grade was developed based on independent risk factors, including gender, Tibetan ethnicity, age, IRBBB, AF, ST, and TC. Points are assigned to each independent factor by drawing a vertical line to the points scale. The total points for an individual correspond to their risk of developing PH. Patients were then classified into high-risk and low-risk subgroups according to the total score's cut-off value (cut-off value: 45), which was determined based on the ROC curve (Fig. 3 A). The risks for the two groups were evaluated in both the derivation and validation sets. In the derivation set, the risk of PH in the

high-risk group was significantly higher than in the low-risk group (odds ratio [OR]: 4.210, 95% confidence interval [CI]: 3.715-4.775) (Fig. 3 B), as was also observed in the validation set (odds ratio [OR]: 4.207, 95% confidence interval [CI]: 3.476-5.102) (Fig. 3 C).

In the PH≥II grade group, a predictive Nomogram^{II} for PH≥II grade was developed using independent risk factors, including Tibetan ethnicity, age, RAD, HVRV, IRBBB, AF, PP, ST and TC. Based on the cut-off value of the total score (cut-off value: 76), determined in line with the ROC curve, patients were categorised into high-risk and low-risk subgroups (Fig. 3 D). The risks for the two groups were evaluated in both the derivation and validation sets. In the derivation set, the risk of PH in the high-risk group was significantly greater than in the low-risk group (odds ratio [OR]: 11.591, 95% confidence interval [CI]: 9.128-14.845) (Fig. 3 E), a finding that was replicated in the validation set (odds ratio [OR]: 7.103, 95% confidence interval [CI]: 5.106-9.966) (Fig. 3 F)

223 .




Figure 3. Nomogram for predicting PH and risk stratification based on total score. (A-C) Nomogram^I for the prediction of PH≥I grade in the PH≥I grade group. Points for each independent factor are summed to calculate total points, determining the corresponding 'risk' level. Patients were divided into 'High-risk' and 'Low-risk' subgroups according to the cutoff of the total

points (A). Histograms illustrate the odds ratio (OR) comparing the 'High-risk' group to the 'Low-risk' group in the derivation set (B) and validation set (C). (D-F) Nomogram^{II} for predicting PH≥II grade within the PH≥II grade group: Similarly, points from each independent factor are totalled, and the corresponding 'risk' level is ascertained. Patients are divided into 'High-risk' and 'Low-risk' groups based on the cut-off value of the total points (D). Histograms display the OR for the 'High-risk' group compared to the 'Low-risk' group in the derivation (E) and validation set (F). *** P < 0.001. (G) Screenshot of dynamic Nomogram^{II}'s web page.




Figure 4. Receiver operating characteristic (ROC) curves and area under the curve (AUC) for Nomogram^I in PH≥I and Nomogram^{II} in PH≥II grade groups. (A-F) In the PH≥I grade group, the ROC and corresponding AUC of Nomogram^I and independent factors in the derivation set (A-C) and validation set (D-F). (G-L) In the PH≥II grade group, the ROC and corresponding AUC




Figure 5. Calibration plots and Hosmer-Lemeshow test results for Nomogram^I in PH≥I and Nomogram^{II} in PH≥II grade groups. (A-B) In the PH≥I grade group, the calibration plots of Nomogram^I in the derivation set (A) and the validation set (B). (C-D) In the PH≥II grade group, the calibration plots of Nomogram^{II} in the derivation set (C) and the validation set (D). (E) In the

PH≥I grade group, Hosmer-Lemeshow test results for Nomogram^I in the derivation set and the validation set. (F) In the PH≥II grade group, Hosmer-Lemeshow test results for Nomogram^{II} in the derivation set and the validation set.

Assessment and validation of Nomogram^I in the $PH \ge I$ grade group and Nomogram^{II} in the $PH \ge II$ grade group

In the PH≥I grade group, Nomogram¹ was developed to predict the risk of PH≥I grade, utilising the AUC to assess its discriminative ability. The AUC value for Nomogram¹ was 0.716 (95% confidence interval [CI]: 0.701 - 0.731) in the derivation set (Fig 4. A) and 0.718 (95% confidence interval [CI]: 0.695 - 0.741) in the validation set (Fig 4. D). Furthermore, ROC curves were used to compare the discriminative capacity of Nomogram¹ and single independent factors in predicting PH≥I grade. Notably, the AUC of Nomogram¹ was significantly higher than that of any single independent factor in the derivation (Fig 4. B, C) and the validation set (Fig 4. E, F). The calibration curves for the derivation set (Fig 5. A) and the validation set (Fig 5. B) demonstrated high agreement between predicted and actual values, indicating that Nomogram¹ accurately predicts PH≥I grade. The results of the Hosmer-Lemeshow test in both the derivation set (P=0.109 > 0.05) and the validation set (P=0.317 > 0.05) further confirmed the effective performance of Nomogram¹ (Fig 5. E).

Nomogram^{II} was developed to predict the risk of PH≥II grade. The AUC for Nomogram^{II} was 0.844 (95% confidence interval [CI]: 0.823 - 0.865) in the derivation set (Fig 4. G) and 0.801 (95% confidence interval [CI]: 0.763 - 0.838) in the validation set (Fig 4. J). Furthermore, ROC curves were used to compare the discriminative capacity of Nomogram^{II} and individual

independent factors in predicting PH≥II grade. The AUC of Nomogram^{II} was significantly higher than that of any single independent factor in the derivation set (Fig 4. H, I) and the validation set (Fig 4. K, L). The calibration curves for the derivation set (Fig 5. C) and the validation set (Fig 5. D) demonstrated high agreement between the predicted and actual values, indicating that Nomogram^{II} accurately predicts PH≥II grade. Additionally, the results of the Hosmer-Lemeshow test in the derivation set (P=0.377 > 0.05) and the validation set (P=0.127 > 0.05) further confirmed the good performance of Nomogram^{II} (Fig 5. F).

Clinical utility of Nomogram^I and Nomogram^{II}

In the PH≥I grade group, the clinical utility of Nomogram^I for predicting the risk of PH≥I grade was assessed using DCA. This analysis revealed a significant net benefit with a threshold probability range of 20% to 91% in the derivation set (Fig 6. A) and 14% to 74% in the validation set (Fig 6. B). Moreover, the DCA curve from the derivation set indicated that the clinical predictive capability of Nomogram^I surpassed that of any single independent factor, a finding that was corroborated in the validation set (Fig 6. C, D).

In the PH≥II grade group, the clinical utility of Nomogram^{II} for predicting the risk of PH≥II grade was evaluated using DCA, which showed a clear net benefit within the threshold probability range of 1% to 70% in the derivation set (Fig 6. E) and 1% to 82% in the validation set (Fig 6. F). Additionally, the DCA curve for the derivation set demonstrated that the clinical predictive effectiveness of Nomogram^{II} exceeded that of any single independent factor, a conclusion that was also confirmed in the validation set (Fig 6. G, H).




Figure 6. Decision curve analysis (DCA) for Nomogram^I in the PH≥I grade and Nomogram^{II} in the PH≥II grade group. (A-D) In the PH≥I grade group, the DCAs of Nomogram^I and independent factors in the derivation (A, C) and validation set (B, D). (E-H) In the PH≥II grade group, the DCAs of Nomogram^{II} and independent factors in the derivation (E, G) and validation set (F, H).

٠,	

305	Comparison b	etween Nomogran	n ^I and Nomogran
3U3	Comparison b	etween Nomogram	i ana Nomogran

In the PH≥I grade group, when comparing Nomogram^I to Nomogram^{II}, Nomogram^I exhibited an IDI of -0.0012 (95% CI: -0.0032 to 0.0009, p=0.2777), a categorical NRI of 0.0117 (95% CI: -0.0004 to 0.0237, p=0.0575), and a continuous NRI of -0.2423 (95% CI: -0.2992 to -0.1854, p<0.001) in predicting the risk of PH≥I grade.

In the PH≥II grade group, compared to Nomogram^I, Nomogram^{II} demonstrated an IDI of 0.0366 (95% CI: 0.0247 to 0.0485, p<0.001), a categorical NRI of 0.0301 (95% CI: 0.0093 to 0.0510, p<0.05), and a continuous NRI of 0.2785 (95% CI: 0.1824 to 0.3745, p<0.001) for predicting the risk of PH≥II grade.

These results indicate that Nomogram^{II} outperformed Nomogram^I in terms of IDI and NRI values.

Website of Nomogram^{II}

Patients and physicians can calculate the risk of pulmonary hypertension through a free web-based dynamic Nomogram^{II} (https://dapeng.shinyapps.io/dynnomapp-1/).

Discussion

A significant portion of the global population lives in high-altitude areas such as the Tibetan Plateau, Ethiopian Highlands, Andes Mountains, and Pamir Plateau. These regions are marked by an extremely hypoxic environment that leads to alveolar hypoxia, posing severe risks to the cardiopulmonary system. One such risk is the development of PH, which occurs through mechanisms like hypoxic pulmonary vasoconstriction and pulmonary vascular remodelling

(Burtscher, Gatterer, Burtscher, & Mairbäurl, 2018; Sydykov et al., 2021; Wilkins, Ghofrani, Weissmann, Aldashev, & Zhao, 2015). Accurate, timely diagnosis and early, effective treatment are crucial for the clinical improvement and survival of patients with PH. Without prompt intervention, PH can impair right heart function and ultimately result in fatal right heart failure (Benza et al., 2010; Kim & George, 2019; McGoon et al., 2004). Thus, there is a need to develop a predictive model to estimate the risk of PH, facilitating risk stratification and management. In this study, we analysed routine electrocardiogram examination indicators and basic demographic information to assess the risk of PH. We developed nomograms for the PH≥I grade group and the PH≥II grade group, and the performance of these nomograms was evaluated and validated.

Currently, TTE is widely utilised for large-scale, non-invasive screening of patients at risk for PH (D'Alto et al., 2018; Habib & Torbicki, 2010; Janda, Shahidi, Gin, & Swiston, 2011). However, in plateau regions such as Tibet, medical resources are relatively limited, and remote villages and towns lack the facilities for TTE examinations. ECG examinations, being easy to administer, cost-effective, and feasible for remote delivery through telemedicine, offer a practical alternative (Ismail, Jovanovic, Ramzan, & Rabah, 2023). A retrospective analysis has demonstrated that ECG examination results correlate with clinical parameters reflecting the severity of PH (Michalski et al., 2022). Therefore, in developing this model, we primarily relied on ECG examination results from patients. Utilising ECG results as predictors of PH can significantly aid clinicians in identifying potential PH patients in remote plateau areas, facilitating their access to timely and relevant treatment.

In this study, based on sPAP assessed by TTE examination, patients at risk of PH were classified into grades I-III. We developed and validated two nomograms for the PH≥I grade group

(Nomogram^I) and the PH≥II grade group (Nomogram^{II}), with ECG examination results serving as the primary component for both. Nomogram^I included seven variables: gender, Tibetan ethnicity, age, IRBBB, AF, ST, and TC. Nomogram^{II} incorporated nine variables: Tibetan ethnicity, age, RAD, HVRV, IRBBB, AF, PP, ST, and TC (Fig 3. A, D). These variables are readily available from routine ECG examinations. Additionally, patients were categorised into high-risk and low-risk groups based on the cut-off value of the total score in the nomogram, with the OR value for the high-risk group being significantly higher than that of the low-risk group (Fig 3). Therefore, both nomograms offer a useful and straightforward method for in-depth evaluation, even without medical professional intervention. Both Nomogram^I and Nomogram^{II} demonstrated good calibration and clinical utility (Fig 5, 6), though ROC analysis revealed that the AUC for Nomogram^{II} was higher than that for Nomogram^I (0.844 vs 0.716). IDI and NRI are recognised indicators that describe improved accuracy in predicting binary, multi-classification, or survival outcomes (Wang, Cheng, Seaberg, & Becker, 2020). In a similar vein to a 10-year retrospective cohort study, which constructed two nomograms for hypertension risk prediction and compared them using IDI and NRI values (Deng et al., 2021), we used IDI and NRI to evaluate the performance of Nomogram^I and Nomogram^{II}. Our findings indicated no significant difference between Nomogram^I and Nomogram^{II} in the PH≥I grade group; however, Nomogram^{II} exhibited superior performance compared to Nomogram^I in the PH≥II grade group, thus demonstrating its enhanced predictive capability. So, we created an online dynamic Nomogram^{II} for doctors and patients to calculate the risk of PH (Fig 3. G).

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

In this study, age and Tibetan ethnicity were identified as independent predictors of PH, a finding that aligns with conclusions from a single-centre, cross-sectional study among native

Tibetans in Sichuan Province, China (Gou et al., 2020). We hypothesise that this association may be due to the longer exposure to the hypoxic environment at high altitudes experienced by older individuals and Tibetans, promoting hypoxic contraction of pulmonary blood vessels and subsequent pulmonary vascular remodelling, thereby leading to PH. Additionally, the occurrence of AF emerged as an independent predictor of PH with the highest OR values in both nomograms (Table 2, 3). PH is known to be characterised by pulmonary vascular remodelling, which can induce fibrosis and excessive myocardial apoptosis, ultimately contributing to AF (Yi et al., 2023), a finding that corroborates our results. Nonetheless, it was observed that no single predictor alone was effective in distinguishing PH, exhibiting poor clinical utility compared to the comprehensive approach offered by the nomogram (Fig 4, Fig 6).

Our study has several limitations. Firstly, TTE serves only as a screening method for PH and is not the gold standard; its results merely indicate the risk of PH in the examined individuals. Secondly, given the constrained medical resources in remote areas, we primarily incorporated readily ECG results and basic demographic information into the nomograms, resulting in a relatively simple set of independent predictors. Lastly, the dataset for this study was exclusively sourced from Tibet, China, meaning the validation of the nomograms lacks external validation sets.

Conclusion

We have developed a reliable and straightforward nomogram to predict the risks associated with PH, demonstrating satisfactory discrimination and calibration. Upon rigorous validation using external datasets, the nomogram has shown clinical utility and favourable predictive accuracy. It is anticipated to serve as an effective and convenient clinical tool for assessing the risk

392 of PH in populations residing at high altitudes. 393 394 Acknowledgements 395 This study was funded by the Talent Program of Army Medical University (No. 2019R038). 396 397 **Statements and Declarations** 398 The authors have no conflict of interest. 399 400 Data availability statement 401 Source data files have been provided. 402 403 References 404 405 Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., . . . 406 McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the 407 Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management 408 (REVEAL). Circulation, 122:164-172. doi:10.1161/circulationaha.109.898122 409 410 Burtscher, M., Gatterer, H., Burtscher, J., & Mairbäurl, H. (2018). Extreme Terrestrial 411 Environments: Life in Thermal Stress and Hypoxia. A Narrative Review. Front Physiol, 9:572. 412 doi:10.3389/fphys.2018.00572 413 414 D'Alto, M., Bossone, E., Opotowsky, A. R., Ghio, S., Rudski, L. G., & Naeije, R. (2018). 415 Strengths and weaknesses of echocardiography for the diagnosis of pulmonary hypertension. Int J 416 Cardiol, 263: 177-183. doi:10.1016/j.ijcard.2018.04.024 417 Deng, X., Hou, H., Wang, X., Li, Q., Li, X., Yang, Z., & Wu, H. (2021). Development and 418 419 validation of a nomogram to better predict hypertension based on a 10-year retrospective cohort 420 study in China. Elife, 10. doi:10.7554/eLife.66419 421 422 Dunham-Snary, K. J., Wu, D., Sykes, E. A., Thakrar, A., Parlow, L. R. G., Mewburn, J. D., . . . 423 Archer, S. L. (2017). Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to

- 424 Medicine. Chest, 151: 181-192. doi:10.1016/j.chest.2016.09.001
- 425
- 426 Gassmann, M., Cowburn, A., Gu, H., Li, J., Rodriguez, M., Babicheva, A., . . . Zhao, L. (2021).
- 427 Hypoxia-induced pulmonary hypertension-Utilizing experiments of nature. Br J Pharmacol, 178:
- 428 121-131. doi:10.1111/bph.15144
- 429
- 430 Gou, Q., Shi, R., Zhang, X., Meng, Q., Li, X., Rong, X., . . . Chen, X. (2020). The Prevalence and
- 431 Risk Factors of High-Altitude Pulmonary Hypertension Among Native Tibetans in Sichuan
- 432 Province, China. High Alt Med Biol, 21: 327-335. doi:10.1089/ham.2020.0022
- 433
- 434 Habib, G., & Torbicki, A. (2010). The role of echocardiography in the diagnosis and management
- 435 of patients with pulmonary hypertension. Eur Respir Rev, 19: 288-299.
- 436 doi:10.1183/09059180.00008110
- Hoeper, M. M., Humbert, M., Souza, R., Idrees, M., Kawut, S. M., Sliwa-Hahnle, K., . . . Gibbs, J.
- 438 S. (2016). A global view of pulmonary hypertension. Lancet Respir Med, 4: 306-322.
- 439 doi:10.1016/s2213-2600(15)00543-3
- 440
- Hong, C., Chen, R., Hu, L., Liu, H., Lu, J., Zhuang, C., . . . Zheng, Z. (2023). Aetiological
- distribution of pulmonary hypertension and the value of transthoracic echocardiography screening
- in the respiratory department: A retrospective analysis from China. Clin Respir J, 17: 536-547.
- 444 doi:10.1111/crj.13623
- 445
- 446 Ismail, A. R., Jovanovic, S., Ramzan, N., & Rabah, H. (2023). ECG Classification Using an
- 447 Optimal Temporal Convolutional Network for Remote Health Monitoring. Sensors (Basel), 23:
- 448 doi:10.3390/s23031697
- 449
- Janda, S., Shahidi, N., Gin, K., & Swiston, J. (2011). Diagnostic accuracy of echocardiography for
- 451 pulmonary hypertension: a systematic review and meta-analysis. Heart, 97: 612-622.
- 452 doi:10.1136/hrt.2010.212084
- 453
- Julian, C. G., & Moore, L. G. (2019). Human Genetic Adaptation to High Altitude: Evidence from
- 455 the Andes. Genes (Basel), 10. doi:10.3390/genes10020150
- 456
- 457 Kim, D., & George, M. P. (2019). Pulmonary Hypertension. Med Clin North Am, 103: 413-423.
- 458 doi:10.1016/j.mcna.2018.12.002
- 459
- 460 Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020). Pulmonary Hypertension: A Brief Guide for
- 461 Clinicians. Mayo Clin Proc, 95: 1978-1988. doi:10.1016/j.mayocp.2020.04.039
- 462
- 463 McGoon, M., Gutterman, D., Steen, V., Barst, R., McCrory, D. C., Fortin, T. A., & Loyd, J. E.
- 464 (2004). Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP
- 465 evidence-based clinical practice guidelines. Chest, 126(1 Suppl), 14s-34s.
- 466 doi:10.1378/chest.126.1_suppl.14S
- 467

- 468 Michalski, T. A., Pszczola, J., Lisowska, A., Knapp, M., Sobkowicz, B., Kaminski, K., &
- 469 Ptaszynska-Kopczynska, K. (2022). ECG in the clinical and prognostic evaluation of patients with
- 470 pulmonary arterial hypertension: an underestimated value. Ther Adv Respir Dis, 16:
- 471 17534666221087846. doi:10.1177/17534666221087846

- 473 Moore, L. G., Niermeyer, S., & Zamudio, S. (1998). Human adaptation to high altitude: regional
- 474 and life-cycle perspectives. Am J Phys Anthropol, Suppl 27: 25-64.
- 475 doi:10.1002/(sici)1096-8644(1998)107:27+<25::aid-ajpa3>3.0.co;2-l

476

- Naeije, R., Richter, M. J., & Rubin, L. J. (2022). The physiological basis of pulmonary arterial
- 478 hypertension. Eur Respir J, 59. doi:10.1183/13993003.02334-2021

479

- 480 Penaloza, D., & Arias-Stella, J. (2007). The heart and pulmonary circulation at high altitudes:
- 481 healthy highlanders and chronic mountain sickness. Circulation, 115: 1132-1146.
- 482 doi:10.1161/circulationaha.106.624544

483

- Rubin, L. J., & Naeije, R. (2023). Sotatercept for pulmonary arterial hypertension: something old
- 485 and something new. Eur Respir J, 61. doi:10.1183/13993003.01972-2022

486

- 487 Ruopp, N. F., & Cockrill, B. A. (2022). Diagnosis and Treatment of Pulmonary Arterial
- 488 Hypertension: A Review. Jama, 327: 1379-1391. doi:10.1001/jama.2022.4402

489

- 490 Shah, A. J., Beckmann, T., Vorla, M., & Kalra, D. K. (2023). New Drugs and Therapies in
- 491 Pulmonary Arterial Hypertension. Int J Mol Sci, 24. doi:10.3390/ijms24065850

492

- 493 Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., . . .
- 494 Souza, R. (2019). Haemodynamic definitions and updated clinical classification of pulmonary
- 495 hypertension. Eur Respir J, 53. doi:10.1183/13993003.01913-2018

496

- 497 Sydykov, A., Mamazhakypov, A., Maripov, A., Kosanovic, D., Weissmann, N., Ghofrani, H. A., ...
- 498 Schermuly, R. T. (2021). Pulmonary Hypertension in Acute and Chronic High Altitude
- 499 Maladaptation Disorders. Int J Environ Res Public Health, 18. doi:10.3390/ijerph18041692

500

- Wang, Z., Cheng, Y., Seaberg, E. C., & Becker, J. T. (2020). Quantifying diagnostic accuracy
- 502 improvement of new biomarkers for competing risk outcomes. Biostatistics.
- doi:10.1093/biostatistics/kxaa048

504

- West, J. B. (2012). High-altitude medicine. Am J Respir Crit Care Med, 186: 1229-1237.
- 506 doi:10.1164/rccm.201207-1323CI

507

- 508 Wilkins, M. R., Ghofrani, H. A., Weissmann, N., Aldashev, A., & Zhao, L. (2015).
- Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation, 131:
- 510 582-590. doi:10.1161/circulationaha.114.006977

Xu, X. Q., & Jing, Z. C. (2009). High-altitude pulmonary hypertension. Eur Respir Rev, 18: 13-17.
doi:10.1183/09059180.00011104
Yi, Y., Tianxin, Y., Zhangchi, L., Cui, Z., Weiguo, W., & Bo, Y. (2023). Pinocembrin attenuates
susceptibility to atrial fibrillation in rats with pulmonary arterial hypertension. Eur J Pharmacol,
960: 176169. doi:10.1016/j.ejphar.2023.176169